Compare · GILD vs MBOT
GILD vs MBOT
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Microbot Medical Inc. (MBOT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and MBOT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $166.72B, about 1418.4x MBOT ($117.5M).
- Over the past year, GILD is up 24.1% and MBOT is down 29.6% - GILD leads by 53.7 points.
- MBOT has been more active in the news (8 items in the past 4 weeks vs 7 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 2 for MBOT).
- Company
- Gilead Sciences Inc.
- Microbot Medical Inc.
- Price
- $134.23-1.50%
- $1.75-2.24%
- Market cap
- $166.72B
- $117.5M
- 1M return
- +5.49%
- -4.12%
- 1Y return
- +24.06%
- -29.64%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 2
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Microbot Medical Inc.
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 42 issued/allowed patents and 23 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Latest MBOT
- Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
- Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
- Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
- Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
- Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Microbot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient Populations